Can Crestor Cause Liver Damage? How to Read the Whole Pattern

Medical review is pending. This page organizes current evidence; it does not replace a clinician’s review of an actual liver panel or authorize a medication change.

Start with a four-channel liver panel, not an ALT verdict

“My liver test is high” usually omits the information that changes the answer. A liver panel contains signals from different biological channels:

• ALT and AST are aminotransferases. They can mark hepatocyte injury, but they do not measure how well the liver is performing every function.
• Alkaline phosphatase (ALP) can point toward a cholestatic or biliary pattern, but it also has non-liver sources; context and, when ordered, GGT help.
• Bilirubin changes the seriousness and differential diagnosis of a pattern. Jaundice is a clinical observation, not simply a high ALT synonym.
• INR and albumin can reflect hepatic synthetic function in the right context, but each has causes outside liver injury and should not be interpreted alone.

The result that matters is the pattern across channels, its change from baseline, symptoms, and timing. This is why the current Crestor label does not give patients a one-number stop rule.

If the concern is actually muscle pain, weakness, or a high creatine kinase result, use the Crestor muscle-pain guide. Myopathy and hepatic dysfunction are separate label warnings, and mixing CK with ALT produces a bad decision record.

What the current Crestor label actually reports

The May 2026 DailyMed version preserves three useful facts from the prescribing information’s hepatic-dysfunction section:

1. In pooled placebo-controlled trials, transaminases over three times ULN occurred in 1.1% with Crestor and 0.5% with placebo [1].
2. In most cases, changes appeared soon after initiation, were transient and asymptomatic, and resolved or improved either during continued therapy or after a brief interruption [1].
3. Rare fatal and nonfatal hepatic failure has been reported after marketing, but voluntary reports cannot establish a reliable frequency or prove causality in every case [1].

The 1.1% and 0.5% comparison is more informative than presenting the Crestor number without background. It is still a laboratory endpoint—not the incidence of jaundice, liver failure, or irreversible injury.

The label also says to consider liver enzyme testing before initiation and when clinically indicated thereafter [1]. It does not prescribe a universal annual panel, a mandatory 12-week check for every person, or an automatic stop after one mildly abnormal value.

The pooled rosuvastatin safety analysis and JUPITER trial add broader trial context, but neither turns a group-average laboratory signal into an individual injury forecast [4,5].

The Liver-Panel Pattern Map

The pattern map is not a score. It helps a clinician see what kind of question the results pose.

Add a fifth strip beneath the map: timeline and co-exposures. Record the Crestor start or dose-change date, all prescription and OTC additions, supplements, alcohol pattern, recent infection, known fatty-liver or cirrhosis status, and any abdominal or systemic symptoms.

This layout resists a common failure mode: comparing today’s ALT with a generic online cutoff while ignoring that bilirubin changed, ALP did not, or the abnormality predated rosuvastatin.

A selected DILI registry is not a risk calculator

The U.S. Drug-Induced Liver Injury Network prospectively evaluated 1,188 people referred with suspected DILI between 2004 and 2012. After formal adjudication, 22 cases were considered definitely, highly likely, or probably attributable to a statin; four involved rosuvastatin. Across the statin cases, the investigators observed hepatocellular and cholestatic presentations, latency from 34 days to more than 10 years, and autoimmune features in some cases [3].

Those observations are useful because they show what rare, clinically apparent injury can look like. They do not mean 4 of every 1,188 rosuvastatin users are injured. Everyone in the denominator already had suspected drug-related liver injury and had entered a specialty registry. Nor can four rosuvastatin cases establish that it is safer or riskier than atorvastatin.

That last point matters when considering a switch. The Crestor versus Lipitor comparison should integrate LDL potency, interactions, kidney function, prior tolerance, and treatment goals rather than turning four selected case reports into a ranking.

Fatty liver and decompensation belong on opposite sides of the page

Metabolic fatty liver commonly coexists with the very cardiovascular risk that prompts statin therapy. Treating “fatty liver” and “liver failure” as synonyms can withhold effective prevention from the wrong person.

The 2023 AASLD practice guidance states:

“Statins are safe and recommended for CVD risk reduction in patients with NAFLD across the disease spectrum, including compensated cirrhosis” [2]

Locator: Rinella and colleagues, AASLD Practice Guidance, “Guidance statements,” statement 1 following the dyslipidemia section.

Limitation: this is class-wide guidance for cardiovascular risk reduction in NAFLD. It does not say rosuvastatin treats steatohepatitis, erase the need to investigate a new abnormal panel, or include decompensated cirrhosis in the quoted recommendation.

The boundary in the current Crestor label is explicit: acute liver failure or decompensated cirrhosis is a contraindication [1]. It also notes that chronic alcohol liver disease can increase rosuvastatin exposure. Someone with compensated fatty liver and someone with jaundice, ascites, encephalopathy, or known decompensation are not variants of the same scenario.

The rosuvastatin hepatic-impairment guide covers this disease-state boundary in more depth. It should be used with the prescribing clinician, not as a self-classification tool.

Crestor’s pharmacology changes the interaction question—not the existence of risk

Rosuvastatin is not extensively metabolized; the label says about 10% of a radiolabeled dose is recovered as metabolite, primarily N-desmethyl rosuvastatin. It also depends on transporters including OATP1B1 and BCRP [1,6]. That differs from atorvastatin’s prominent CYP3A4 pathway.

But “not mainly CYP3A4-metabolized” does not mean “cannot affect the liver.” Transporter interactions, severe renal impairment, Asian ancestry, and higher dosing are prominent in Crestor exposure and myopathy decisions. They should not be casually relabeled as proven predictors of hepatic injury. The rosuvastatin interaction profile separates exposure limits by co-medication instead of reducing them to a generic liver warning.

The 40-mg tablet deserves the same precision. Current labeling reserves 40 mg for patients who have not reached LDL goals on 20 mg. The label explicitly identifies greater myopathy risk at 40 mg, but its hepatic section reports the pooled Crestor-versus-placebo transaminase comparison rather than a clean liver-risk percentage for each dose [1]. The AHA scientific statement likewise separates routine enzyme abnormalities from rare severe statin-associated hepatic injury [7].

For timing questions, see whether Crestor needs to be taken at night. Time of day does not substitute for the indication, dose, interaction, or liver-context review.

A clinically indicated review is different from routine surveillance

The label’s phrase “when clinically indicated” becomes concrete when there is a new symptom, a meaningful lab trend, substantial alcohol exposure, known liver disease, a new interacting medicine, or another plausible cause that needs separation.

Its urgent pattern is also concrete: if serious hepatic injury occurs with clinical symptoms and/or hyperbilirubinemia or jaundice, Crestor should be promptly discontinued. That is a prescriber-facing label action, not encouragement to conduct a home stop-and-restart test. New jaundice, dark urine, severe malaise, or significant right-upper-abdominal symptoms warrant prompt medical assessment.

An asymptomatic result may still deserve timely review, but the work is diagnostic: repeat or verify when appropriate, compare with baseline, classify the panel, review every exposure, and assess competing causes. The rosuvastatin monitoring guide can help organize the visit, but it cannot replace the patient-specific plan.

Shortcuts the evidence does not support

• Crestor is “liver safe” because it bypasses CYP3A4. Metabolism and hepatic adverse-event evidence are different questions.
• Every ALT rise is harmless. The pattern and symptoms decide how seriously the result must be evaluated.
• Every ALT rise is Crestor DILI. Fatty liver, infection, alcohol, biliary disease, another drug, and supplements remain competing explanations.
• The 40-mg strength has a current label liver rate of 1.1%. The 1.1% figure is the pooled Crestor rate versus 0.5% placebo, not a 40-mg-only estimate.
• Statins treat fatty liver. AASLD recommends them for cardiovascular risk reduction; the same guidance says they should not be used as a histologic treatment for NASH.
• No early problem rules out a later one. Rare adjudicated DILI cases had widely variable latency.